A recent study presented at Digestive Disease Week 2026 highlights the potential of duodenal mucosal resurfacing (DMR) as a minimally invasive procedure to mitigate weight regain after discontinuing GLP-1 medications like Ozempic and semaglutide. In a randomized, sham-controlled trial, participants who underwent DMR regained significantly less weight compared to those who received a sham procedure, with results indicating that the treatment may effectively “reset” metabolic processes in the upper small intestine.

The clinical significance of these findings is underscored by the fact that approximately 70% of individuals who stop using GLP-1 therapies experience substantial weight regain within 18 months. The DMR procedure targets the duodenum, where critical hormones involved in metabolism are produced. By abating the unhealthy mucosal layer, the treatment promotes the regeneration of healthier tissue, potentially stabilizing metabolism and preserving the weight loss benefits achieved during medication use. In the trial cohort, those who received DMR regained only about 7 pounds on average, retaining over 80% of their weight loss, while the control group regained nearly twice as much.

The implications for future research and clinical practice are significant. DMR may represent a paradigm shift in weight management strategies, particularly for patients seeking alternatives to long-term pharmacotherapy. As the ongoing REMAIN-1 trial progresses, with over 300 participants enrolled, the anticipated results could pave the way for a novel intervention that addresses a critical unmet need in obesity treatment, potentially reducing reliance on continuous medication while enhancing metabolic health outcomes.

Source: sciencedaily.com